Correlation between thyroid volume and humoral thyroid autoimmunity after radioiodine therapy in Graves' disease.
نویسندگان
چکیده
BACKGROUND Graves' disease is an autoimmune disorder with the presence of TSH receptor autoantibodies (TRAb). TRAb are produced mainly by lymphocytes infiltrating the thyroid gland. The aim of this study was to investigate the influence of the reduction of thyroid volume (TV) on TRAb level after radioiodine (RAI) administration in a group of patients with Graves' disease. MATERIAL AND METHODS A retrospective chart review of 36 patients with Graves' disease (age range 18-67 yrs; Me 46 yrs; mean age ± SD 43 yrs ± 13.0 yrs) treated with RAI administration (the mean dose of RAI ± SD was 46.1 mCi ± 21.7 mCi ) was performed. Data concerning TV, TRAb, TSH, and fT4 was collected immediately before administration of radioiodine and 18-36 months thereafter. Data was collected before the first administration of RAI and 18-36 months after the last administration of RAI for patients treated with repeated doses of RAI. RESULTS Before treatment, mean male (n = 4) TV was 27.9 ml ± 9.6 ml and mean female (n = 32) TV was 20.6 ml ± 12.7 ml. Mean TV was 2.4 ml ± 1.7 ml(males) and 5.3 ml ± 10.9 ml (females) after therapy. There was an extremely significant difference between mean TV before RAI administration and after 18-36 months. There was an extremely significant difference between the mean serum level of TRAb before and 18-36 months after RAI therapy. No significant correlation between percentage reduction of TV and percentage reduction of serum level of TRAb was found. CONCLUSIONS 1. Decrease of thyroid gland volume after radioiodine therapy is followed by a significant decrease of the level of TRAb after 18-36 months. 2. TRAb concentration is positively correlated with thyroid gland volume. 3. Percentage reduction of TRAb is not correlated with percentage reduction of thyroid volume.
منابع مشابه
TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study.
INTRODUCTION Autoimmunity against the TSH receptor is a key pathogenic element in Graves' disease. The autoimmune aberration may be modified by therapy of the hyperthyroidism. OBJECTIVE To compare the effects of the common types of therapy for Graves' hyperthyroidism on TSH-receptor autoimmunity. METHODS Patients with newly diagnosed Graves' hyperthyroidism aged 20-55 years were randomized ...
متن کاملThymic Involution After Radioiodine Therapy for Graves Disease: Relationships With Serum Thyroid Hormones and TRAb
Context The mechanisms of thymic hyperplasia in Graves disease and its involution after radioiodine (I-131) therapy remain unknown. Objective To examine whether computed tomography (CT) findings of the thymus in patients with Graves disease change before and 6 months after I-131 therapy and to elucidate factors that affect these changes. Design Setting A retrospective, single-center study w...
متن کاملDisappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens.
BACKGROUND The development of antibodies to thyroid peroxidase, thyroglobulin, and thyroid-stimulating hormone (TSH) receptor is a main feature of autoimmune thyroid diseases. OBJECTIVE To investigate whether complete removal of thyroid antigens results in the abatement of humoral thyroid autoimmunity. DESIGN Retrospective chart review study of patients treated and monitored with a standard...
متن کاملRadioiodine (131-I) treatment for Graves’ disease: Geant4 Monte Carlo simulation for patient personalized dose estimation
Background: Reliable estimation of radiation-absorbed dose is necessary to evaluate the benefits and the risks of radiopharmaceuticals used for diagnostic or therapeutic purposes in nuclear medicine. Materiel and Methods: This study included 47 patients treated with iodine-131 for Graves’ disease. A comparative study between Geant4 Monte Carlo simulation and MIRD formalism was carried out to ev...
متن کامل[Correlation between thyroid volume determined either by ultrasound or by scintigraphy and its implications in dosimetric radioiodine calculations in Graves disease treatment].
INTRODUCTION Graves disease (GD) is the most common cause of hiperthyroidism, and the most common treatment options are surgery, antithyroid drugs and radioiodine therapy. In radiodosimetric calculations to determine radioiodine dosage it is possible to use thyroid volume estimatives based on ultrasound or scintigraphy. OBJECTIVE The present study aimed to correlate these methodologies emphas...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Endokrynologia Polska
دوره 63 1 شماره
صفحات -
تاریخ انتشار 2012